<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747720</url>
  </required_header>
  <id_info>
    <org_study_id>DR-002-1373</org_study_id>
    <nct_id>NCT01747720</nct_id>
  </id_info>
  <brief_title>Vitamin D and Mammographic Breast Density</brief_title>
  <acronym>EVIDENSE</acronym>
  <official_title>A Randomized Double-blind Placebo-controlled Trial of the Effect of Vitamin D Supplementation on Breast Density in Premenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quebec Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is some evidence that vitamin D could be used to reduce breast cancer risk. Randomized&#xD;
      controlled trials would provide definitive evidence about this effect. However, trials with&#xD;
      breast cancer as outcome are expensive and time-consuming. Use of surrogate outcomes has been&#xD;
      advocated to accelerate progress in the identification of interventions that could prevent&#xD;
      breast cancer. Mammographic breast density is one of the strongest breast cancer risk&#xD;
      indicators and is already used as a surrogate outcome in several breast cancer prevention&#xD;
      trials. The aim of this double-blind randomized controlled trial is to determine whether&#xD;
      daily oral supplementation with vitamin D3 (1,000, 2,000 or 3,000 IU) over a period of 1 year&#xD;
      reduces breast density in premenopausal women compared to placebo. A total of 376 women (94&#xD;
      per arm) who live in Quebec City will be recruited. Showing that vitamin D reduces breast&#xD;
      density would provide strong support for the idea that vitamin D can be a safe and&#xD;
      inexpensive approach for the prevention of breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      - to determine whether adding oral supplementation with vitamin D3 (cholecalciferol) at doses&#xD;
      of 1,000, 2,000 and 3,000 IU/d to baseline total vitamin D intake over a period of 12 months&#xD;
      reduces mammographic breast density among premenopausal women at moderate to high risk of&#xD;
      breast cancer who reside in the Quebec City area, Canada.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  to assess the net increase in 25(OH)D levels resulting from this vitamin D3&#xD;
           supplementation;&#xD;
&#xD;
        -  to document the compliance with, and safety of, supplementation with tested doses of&#xD;
           vitamin D3 over one year.&#xD;
&#xD;
      OUTLINE This study is a double-blind, placebo-controlled, randomized trial among&#xD;
      premenopausal women who live in the Quebec City area and have ≥ 20% breast density at&#xD;
      baseline.&#xD;
&#xD;
      The intervention consists of the addition, over baseline total vitamin D intake from food and&#xD;
      supplements, of three different doses of vitamin D3 (1000, 2000 or 3000 IU/day) for a period&#xD;
      of 12 months. There are four arms in the trial:&#xD;
&#xD;
        -  Arm 1: 1,000 IU vitamin D3/d (1 tablet vitamin D 1000 IU + 2 tablets placebo);&#xD;
&#xD;
        -  Arm 2: 2,000 IU vitamin D3/d (2 tablets vitamin D 1000 IU + 1 tablet placebo);&#xD;
&#xD;
        -  Arm 3: 3,000 IU vitamin D3/d (3 tablets vitamin D 1000 IU);&#xD;
&#xD;
        -  Arm 4: placebo (3 tablets placebo/d).&#xD;
&#xD;
      Vitamin D tablets (1000 IU tablets) and the placebo tablets are undistinguishable in size,&#xD;
      shape, color and taste, and are manufactured by the same company.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">May 17, 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mammographic breast density</measure>
    <time_frame>12 months</time_frame>
    <description>Difference in breast density between baseline and at 12 months</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 (cholecalciferol) 1000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral vitamin D3 (cholecalciferol) supplementation, 1000 IU daily, for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 (cholecalciferol) 2000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral vitamin D3 (cholecalciferol) supplementation, 2000 IU daily, for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 (cholecalciferol) 3000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral vitamin D3 (cholecalciferol) supplementation, 3000 IU daily, for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily, for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Vitamin D3 (cholecalciferol) 1000 IU</arm_group_label>
    <arm_group_label>Vitamin D3 (cholecalciferol) 2000 IU</arm_group_label>
    <arm_group_label>Vitamin D3 (cholecalciferol) 3000 IU</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  be premenopausal at baseline;&#xD;
&#xD;
          -  have breast density of at least 20% at baseline;&#xD;
&#xD;
          -  have normal baseline serum calcium (2,12-2,60 mmol/L) and serum creatinine (45-85&#xD;
             μmol/L);&#xD;
&#xD;
          -  agree to have her mammogram at 12 months of follow-up at the same mammography clinic&#xD;
             (same site) as the one where the mammogram at recruitment was done.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  taking &gt; 400 IU/day of supplemental vitamin D and refusing to reduce (≤ 400 IU/day) or&#xD;
             cease such intake;&#xD;
&#xD;
          -  taking &gt; 600 mg/day of supplemental calcium and refusing to reduce (≤ 600 mg/day) or&#xD;
             cease such intake;&#xD;
&#xD;
          -  have contra-indications for use of vitamin D supplementation (hypersensitivity to&#xD;
             vitamin D or its analogues; a history of renal calculi or hypercalcemia,&#xD;
             hypervitaminosis D);&#xD;
&#xD;
          -  taking medication suspected to interact with vitamin D: frequent use of antacids&#xD;
             containing magnesium or aluminium; regular use of anticonvulsants (phenytoin,&#xD;
             phenobarbital), digoxin, cholestyramine, colestipol, orlistat, mineral oil;&#xD;
&#xD;
          -  have a personal history of breast cancer;&#xD;
&#xD;
          -  have a personal history of cancer other than non-melanoma skin cancer within 5 last&#xD;
             years;&#xD;
&#xD;
          -  have had breast reduction or augmentation including breast implantation (or planning&#xD;
             to undergo such surgery during the trial);&#xD;
&#xD;
          -  be pregnant or planning a pregnancy in the next year.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Brisson, M.D., Sc.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du CHU de Québec, et Faculté de médecine de l'Université Laval</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de recherche du CHU de Québec, Hôpital du Saint-Sacrement</name>
      <address>
        <city>Québec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>mammographic breast density</keyword>
  <keyword>vitamin D</keyword>
  <keyword>prevention</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will not share IPD. Results of the study are published in Cancer Epidemiology, Biomarkers and Prevention.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

